Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
暂无分享,去创建一个
M. Paesmans | T. Calandra | C. Viscoli | W. Kern | H. Gaya | J. Klastersky | D. Engelhard | O. Marchetti | A. Skoutelis | H. Akan | A. Cometta | R. de Bock | M. Glauser | M. Vandenbergh | S. Zinner | F. Crokaert | A. Padmos | V. Korten | M. Vandercam | R. D. Bock | Korten
[1] T. Calandra,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[2] Robert E. Johnson,et al. From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, JAMA.
[3] G. Moran,et al. Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, MMWR. Morbidity and mortality weekly report.
[4] F. Mandelli,et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] R. Stephan,et al. Prevalence of colonisation and resistance patterns of vancomycin-resistant enterococci in healthy, non-hospitalised persons in Switzerland. , 2001, Swiss medical weekly.
[6] R. Ramphal,et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Laseur,et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. , 2000, The Journal of antimicrobial chemotherapy.
[8] B. Murray,et al. Vancomycin-resistant enterococcal infections. , 2000, The New England journal of medicine.
[9] H. Tate,et al. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. , 1996, The Journal of antimicrobial chemotherapy.
[10] M. Paesmans,et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.
[11] S. Steinberg,et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Elaine Larson,et al. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[13] R. Feld,et al. Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial , 1994, Annals of Internal Medicine.
[14] K. Singh,et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] H D Isenberg,et al. Vancomycin-Resistant Enterococcus faecium in Hospitalized Children , 1992, Infection Control & Hospital Epidemiology.
[16] B. Kramer,et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study , 1992, Antimicrobial Agents and Chemotherapy.
[17] Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. , 1991, The Journal of infectious diseases.
[18] S. Steinberg,et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. , 1988, Annals of internal medicine.